Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies

Haematologica

Volumn 93, Issue 9, 2008, Pages 1436-1438

  Fernández, Angel ^a   De Arriba, Felipe ^a   Rivera, José ^a   Heras, Inmaculada ^a   Vicente, Vicente ^a   Lozano, María Luisa ^a  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

Hematologic malignancies; Mobilization; Paclitaxel

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; PACLITAXEL; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

APHERESIS; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; LEUKAPHERESIS; SALVAGE THERAPY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; SALVAGE THERAPY;

EID: 50849101391     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13056     Document Type: Letter

References (11)

1. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study. Am J Clin Oncol 1998;21:553-6.
2. Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, et al. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Onc 1997;8 (Suppl 1):129-31.
3. Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13: 1714-9.
4. Gomez-Espuch J, Moraleda JM, Ortuño F, Lozano ML, Ayala F, Vallejo C, et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant 2000;25:231-5.
5. Shea TC. Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. Semin Oncol 1997;24 (Suppl 2): S2-105-S2-107.
6. McKibbin T, Burzynski J, Greene R, Ochoa-Bayona J, Tsai TW, Callander N, et al. Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen. Leuk Lymphoma 2007;48:2360-6.
7. Koenigsmann M, Jentsch-Ullrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004;44:777-84.
8. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30.
9. Nervi B, Ramirez P, Holt M, Rettig MP, Ritchey JK, Prior JL, et al. CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy. Blood (ASH Annual Meeting Abstracts) 2006; 108[Abstract 569].
10. Andreeff M, Konoplev S, Wang R-Y, Zeng Z, McQueen T, Shi Y-X, et al. Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: first evidence in patients and potential for abolishing bone marrow microenvironment mediated resistance. Blood (ASH Annual Meeting Abstracts) 2006;108:176a[Abstract 568].
11. Jacoub JF, Suryadevara U, Pereyra V, Colon D, Fontelonga A, Mackintosh FR, et al. Mobilization strategies for the collection of peripheral blood progenitor cells: results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006;34:1443-50.